Cytocristin Vincristine Sulphate 1mg/1ml

About Cytocristin Vincristine Sulphate 1mg/1ml

CYTOCRISTIN Injection

Indications

Vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:

Leukemia, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.

Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.

Multiple myeloma.

Solid tumors, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.

Paediatric solid tumors, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms tumor, retinoblastoma and medulloblastoma.

Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical ster oids may respond to Vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of Vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.

Dosage

Adults: Usually administered intravenously at weekly intervals; recommended dose is 1.4 to 1.5 mg/m2 up to a maximum weekly dose of 2 mg.

Children: The suggested dose is 1.4 to 2 mg/m2 given on a weekly basis with a maximum weekly dose of 2 mg. For children weighing 10 kg or less the starting dose should be 0.05 mg/kg administered as a weekly intravenous injection.

Administration

The concentration of Vincristine Sulphate Injection is 1 mg/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP into an accurate dry syringe, measuring the dose carefully.

Contraindications

Intrathecal administration is usually fatal.

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

Patients who have shown signs of hypersensitivity to Vincristine or to any of the excipients.

Side Effects

Alopecia, sensory loss, paresthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes, muscle wasting, generalized sensorimotor dysfunction

Storage

Store between 2 Deg C and 8 Deg C in refrigerator. Do not freeze. Protect from light.

Trusted Cancer Treatment Solution

Cytocristin Vincristine Sulphate 1mg/1ml is an established anti-cancer drug widely utilized in clinical oncology. It is designed to inhibit cancer cell growth, thereby supporting cancer management protocols. This medication is known for its effectiveness when used as part of a supervised treatment regimen.


Safe Handling and Storage Instructions

For optimal potency and safety, store Cytocristin Vincristine Sulphate at 25C, away from light, moisture, and extreme temperatures. Keep the product in its original packaging and place it out of children's reach. Proper storage helps maintain its efficacy throughout its two-year shelf life.


Professional Use and Dosage Guidelines

This medication must be administered strictly in accordance with your physician's guidance. Dosage and duration are determined by the treating oncologist, considering patient-specific factors. Never attempt to self-administer this drug; professional supervision is mandatory to ensure safety and effectiveness.